Dr. Jason Sicklick

GIST Expert Dr. Jason Sicklick & Team Release New Study on What Drives GIST

In a recent study, researchers at University of California San Diego School of Medicine identified new therapeutic targets that could lead to new treatment options for patients. The study, published in the February 18, 2021 online edition of Oncogene, found that specific cell-to-cell communication influences GIST biology and is strongly associated with cancer progression and metastasis.

By |2021-02-19T08:58:23-05:00February 19th, 2021|GIST Education, News|

Genetic Testing Cost Effective for Newly Diagnosed GIST

UC San Diego Health released a post today titled, "Genetic Testing Cost Effective for Newly Diagnosed GIST" discussing a new paper published in JAMA Network Open by Moores Cancer Center's Dr. Jason Sicklick and colleagues which covered genetic testing for GIST patients.

By |2020-09-28T14:32:47-04:00September 28th, 2020|News, Research|

RARE Partnership in Advocacy, Funding, and Research for Gastrointestinal Stromal Tumor

Partnerships and collaborations are critical to the progress of research in rare diseases. GIST specialist & Pediatric & SDH-Deficient GIST Consortium member, Dr. Jason Sicklick, and LRG member, Debra Melikian, are working together find a cure for succinate dehydrogenase-deficient gastrointestinal stromal tumors (SDH-deficient GIST), a hereditary rare cancer syndrome which claimed the lives of Debra’s husband and her son Merak.

By |2021-01-13T11:53:21-05:00July 14th, 2020|Advocacy, News, Research, SDH-Deficient GIST|

Patient Advocate’s Story Unfolds in RARE Revolution Magazine

Deb Melikian, patient advocate, and Dr. Jason Sicklick, GIST expert & researcher, share the story of their unique partnership which began at an LRG GIST Day of Learning in the rare partners issue of RARE Revolution Magazine.

By |2020-02-04T08:53:11-05:00February 4th, 2020|Advocacy, News, SDH-Deficient GIST|

LRG Webcast Series: Updates on the Temozolomide Trial

Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.

By |2020-07-09T17:44:13-04:00September 16th, 2019|Clinical Trials, SDH-Deficient GIST, Webcast|

New Horizons – Pediatric & SDH-Deficient GIST Consortium Update: A Review with Experts & Advocates

A Pediatric & SDH-Deficient GIST Consortium Update: A Review with Experts & Advocates presented by Jayne Bressington, Becky Owens, and Dr. Jason Sicklick at New Horizons 2019 in Wayne, NJ.

By |2019-08-30T10:37:28-04:00August 30th, 2019|Events, Global, Video|

Life Fest 2018 State of GIST: A Clinical Panel of Experts

State of GIST: A Clinical Panel of Experts Presented by Jason Sicklick, MD, Moores Cancer Center, University of California, San Diego;  and the GIST Experts Panel - Markku Martti Miettinen, MD, National [...]

By |2019-03-20T09:41:54-04:00September 18th, 2018|Events, GIST Education, Video|
Go to Top